Poolbeg Pharma granted US patent related to influenza drug

Poolbeg Pharma has been granted a patent in the United States for the treatment of hypercytokinaemia using its new influenza drug POLB 001.

The US patent covers the use of POLB 001 and related p38 MAP kinase inhibitors for the treatment of “cytokine storm”, including hypercytokinaemia that occurs because of a viral infection, cancer or autoimmune response by reducing the body’s hyperinflammatory response.

POLB 001 is a viral strain agnostic, small molecule immunomodulator being developed to address severe influenza and other acute inflammatory conditions. 

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma

Poolbeg Pharma could reach €1bn valuation

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici for $1.48

Poolbeg Pharma

The role of AI in Drug Discovery and Healthcare

Artificial intelligence (AI) has emerged as a promising solution with significant potential to revolutionize drug discovery and development. The global AI in healthcare market, valued at USD 16.3 billion in 2022, is projected to grow at a CAGR

Poolbeg Pharma

The impact of Artificial Intelligence in the pharmaceutical industry

Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new

Poolbeg Pharma

Amryt trio join Poolbeg leadership team

Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. These experienced professionals will assume pivotal roles within

Poolbeg Pharma

Poolbeg Pharma Immunomodulator II patent granted in Japan

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Japanese Patent Office has notified the Company of its official decision

Poolbeg Pharma

AI is taking drug discovery by storm

Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered into partnerships or licensing agreements with AI companies

Poolbeg Pharma

Poolbeg Pharma POLB 001 LPS Challenge Trial data to be presented at IUIS

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted

Poolbeg Pharma

Key senior members of former Amryt Pharma leadership join Poolbeg Pharma

Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both

Poolbeg Pharma

Former Amryt Pharma leadership team to join Poolbeg

Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma. David Allmond, John McEvoy and Laura Maher will join the company in the coming months. Allmond will become chief business officer

Poolbeg Pharma

The potential of AI in Drug Discovery and its impact on Healthcare

The discove­ry of new drugs has always been a challe­nging and expensive proce­ss. It involves extensive­ timeframes and significant costs, which have long highlighte­d the need for re­form in this critical field. Despite pre­vious efforts to accelerate drug

Poolbeg Pharma

Could AI save us from the next pandemic?

The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While the pharmaceutical industry scrambled for vaccines and treatments

Poolbeg Pharma

Poolbeg Pharma partners with Nasdaq-listed biopharma company

Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition. Poolbeg said that it will receive funding

No more posts to show